QIAGEN

Sample & Assay Technologies

Bank of America Merrill Lynch
Health Care Conference
New York, May 11, 2010

Roland Sackers, CFO

Forward Looking Statements

Safe Harbor Statement: *Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations from certain events including funding, budgets, and others), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, the management of intellectual property, and the integration of acquisitions of technologies and businesses. In addition certain statements contained in this news release are based on company assumptions, including, but not limited, to revenue allocations based on business segments and/or customer classes. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).*

Regulation G: *The following slides contain certain summary information about QIAGEN N.V.'s sales, gross profit, operating income, net income, and earnings per share over a specific period and the comparable period, which information is presented on a "non-GAAP financial measures" basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review QIAGEN's press releases for information on the company's operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company's reports on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.*

QIAGEN at a Glance

Revenues[1]:	2009:	US$1.010 M	04–09 CAGR: 23%
Net income[2]:	2009:	US$ 200 M	04–09 CAGR 28%
EPS[2]:	2009:	US$ 0.93	04–09 CAGR: 19%

Product Range:

- >500 consumable products
  - Sample Technologies: to collect, separate, purify, isolate, stabilize and store samples
  - Assay Technologies: to make such isolated target information (DNA, RNA, proteins, etc.) visible
- Instrumentation for above consumables

Customers: >400,000

- Academic research
- Pharma/Biotech
- Applied testing (veterinary, forensics etc.)
- Molecular diagnostics

IP (12/09): >2,100 patents
(783 issued, 843 pending, 550+ licensed)

Employees: >3,500 employees based in >35 subsidiaries

(1) Revenues 2004 excluding synthetic DNA business sold in Q2 2004.

(2) Excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R).

Sample & Assay Technologies

Complex sample



Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, ...

Sample Technologies

Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, ...

Pure Analyte

DNA

Assay Technologies

Information

Typical Products: From Sample to Results

Sample & Assay Technologies on Automated Platforms

Sample Technologies

Assay Technologies

Fully Automated Platforms

Sample and Assay Technologies

Technology Leadership



Sales Strength



Growth Drivers



Financials

Sample and Assay Technologies

Technology Leadership



Sales Strength

MDx
Appl. Testing
Pharma
Biomedical
Academia
Inside Sales
E-commerce

MARKETS

Growth Drivers



Financials

Technology and Innovation Leader

Technology Leadership

R&D at QIAGEN:

Investment: Approx. 12% of sales

People: >700 employees in R&D

Multiple locations:

- Germany
- U.S.
- Switzerland
- Singapore
- China

Multiple disciplines:

- Chemistry
- Biology
- Physics
- Engineering and others

Fast, proven innovation cycles:

Stable 4-5% revenue growth from new products launched in last 12 months.

Significant Sales and Marketing Power

Technology Leadership



Sales Strength



Growth Drivers



Financials

QIAGEN's Global Footprint



Q1 2010 percentage of sales based on constant exchange rates

QIAGEN‘s Organic Growth
Sustainable and Industry Leading

Organic Growth Rate Development



Outperforming the Industry

Industry data includes: Illumina, Luminex, Cepheid, Techne, GenProbe, Sigma Aldrich, Bio Rad, Mettler, Meridian, Beckman, Waters, Becton Dickinson, Roche, Thermo, Millipore, Bruker, Celera, Affymetrix, Immucor, QIAGEN, Tecan, Life Technologies

QIAGEN is Addressing Key Growth Markets

Technology Leadership



Sales Strength

Growth Drivers



Financials

Leading Position - Multiple Growth Drivers

Molecular Diagnostics	Applied Testing	Pharmaceutical Industry	Life Science Research
			
■ Prevention ■ Profiling ■ Personalized Healthcare ■ Point of Need	■ Veterinary ■ Forensic ■ Bio defense ■ Food	■ Discovery ■ Development	■ Public ■ Private

SAMPLE Technologies → ASSAY Technologies

Product and Technology Continuum

Molecular Diagnostics

Prevention - Profiling - Personalized Healthcare - Point of Need

Growth Drivers

Market Situation

- High market growth ~15%
- New areas emerging: companion diagnostics, point of need
- MDx allows significant cost reduction in healthcare

QIAGEN‘s Position

- Platforms for all laboratory sub-segments
  (from prevention to point of need)
- Technology scales across all platforms
- Broad assay portfolio : 15 PMA/510K, >40 CE marked, 10 SFDA
- Strong brand, good reputation, powerful infrastructure

Opportunities

- New platform launches 2010 - 2012
- Full assay portfolio, many assays in pipeline
- Personalized medicine and point of need testing

Global In Vitro Diagnostics Market
By Segment

In Vitro Diagnostics
Estimated market volume: ~US$ 33B (2006)
CAGR 2006 – 2010: 7%

Molecular Diagnostics
Estimated market volume: ~US$ 2.4 billion (2006)
CAGR 2006 – 2010: 17%



MDx: Fastest Growing Segment in In Vitro Diagnostics

Note: IVD market estimates vary by source and range between ~$29B–$35B
Source: RBC Capital Markets, Nature Biotechnology (August 2006), Digene internal reports, Recap, Kalorama, BioCentury, L.E.K. Analysis

QIAGEN's 4 "P" Framework in MDx

	LABORYTORY BASED TESTING			POINT OF NEED
	Prevention *Asymptomatic patients* *Goal: Early detection*	**Profiling** *Symptomatic patients* *Goal: Confirm*	**Personalized Healthcare** *Pre-diagnosed patients* *Goal: Guide therapy*	*Rapid turnaround needed* *No laboratory reachable* *Goal: fast result, on spot*
Assay Technologies	Narrow portfolio High volume/<$20/assay	Broad portfolio High value, low volume	Growing portfolio High value, low volume	Emerging segment Instrument <$2k, Assays: $3-30
	Examples • HPV • Chlamydia/NG • 5 additional assays in pipeline • More to come	Examples: • CMV • EBV • HBV • HIV • HCV • Influenza	Examples • KRAS • EGFR • B-RAF • PI3K • Pathogen Genotyping	Examples • careHPV • HAI • Influenza
Instruments	High throughput Continuous load	Random access Continuous load	Random access Continuous load	Portable test systems, Rapid turn around < 2hrs
	QIA*ensemble*	QIA*symphony*	QIA*symphony*	*TBA*
Assay Design	Fast, typically isothermal amplification or no amp	PCR Pyrosequencing	PCR Pyrosequencing	Isothermal amplification

QIAGEN in Molecular Diagnostics

Migrating to Fully Automated Solutions

	PREVENTION	PROFILING	PERSONALIZED HEALTHCARE	POINT OF NEED
2008-2009 Semi - Automated Modules		 		
2009-2010 Fully Automated Integrated Key assays				
> 2010 Fully Automated Fully integrated Assay breadth				

Applied Testing
Multiple Segments, Strong Potential

Market Situation

- Use of molecular methods increasing
- Market growth 15+%

QIAGEN‘s Position

- Focus segments: genetic ID, veterinary
- Growing assay portfolio
- Complete platforms

Opportunities

- Platform strength
- Geographic expansion

Pharmaceutical Industry
Partner From Discovery Through Drug Development to PHC

Market Situation

- Pharma development continues strong
- Discovery soft, impacted by mergers and cost cutting
- Links in development into PHC and CDx

QIAGEN‘s Position

- Perfect partner from discovery to companion diagnostics
- Pharma net sales: ~50% development, ~50% discovery

Opportunities

- Content-based approach (disease/pathway testing panels)
- Companion diagnostics
- New platforms (QIAsymphony RGQ)

Academic Markets
Source of Innovation

Market Situation

- Focus on innovation (stimulus packages U.S., Europe)
- Scientific knowledge in Life Sciences increasing exponentially
- New hot topics emerging faster and faster

QIAGEN‘s Position

- Focused on leadership in core markets
- Among fastest growing companies in academic market
- Strong brand and good reputation

Opportunities

- Innovation and quality leader
- High growth areas: e.g. biomarker discovery
- Stimulus packages

QIAGEN Group
Revenue and EPS Growth 2004 - 2009

$CAGR_{2004-2009}$ = ~23%



$CAGR_{2004-2009}$ = ~19%



2004 revenues excluding synthetic DNA business, sold in Q2 2004.

All figures excluding business integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R).

QIAGEN Group
Operating Cash Flow and Free Cash Flow 2004 - 2009





Free cash flow computed using net cash from operating activities less capital expenditures.

Key Investment Considerations
Strong Growth at Low-Risk

Strong Strategic Position

- Addressing high growth markets
- Focused, complete and technology-leading portfolio
- Critical mass, well functioning global organization
- Global footprint with activities

Innovation is key

- Proven innovation leadership in industry
- 79 product launches in 2009 – 14 in Q1 2010
- 4-5% of revenue growth from new introduced products

Strong Financial Performance

- Exceed Q1 adjusted EPS on strong revenues
- Guidance 2010
  - Revenues: US$ 1,120 – 1,170
  - EPS, adj.: US$ 0.90 – 0.96

Thank you!